Shandong New Time Pharmaceutical Co., LTD
Shandong New Time Pharmaceutical Co., LTD
Explore linked clinical trials.15 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 1 | 2026-09-21 | NCT07829614 | |
| A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) | Neoplasm Metastasis, Neoplasms, Unknown Primary, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cancer of unknown primary site, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-08-12 | NCT07761429 | |
| Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors | Patients With Advanced Solid Tumors | Not yet recruiting | Phase 1 | 2026-06-22 | NCT07661797 | |
| A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-05-12 | NCT07579234 | |
| A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2025-12-31 | NCT07312188 | |
| Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 3 | 2025-07-01 | NCT07046273 | |
| A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Enrolling by invitation | Phase 3 | 2025-03-07 | NCT06863987 | |
| Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria | Acute Urticaria | Recruiting | Phase 3 | 2025-02-11 | NCT06819774 | |
| Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding | Digestive System Diseases, Gastrointestinal Hemorrhage, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Peptic Ulcer Hemorrhage, digestive system disorder | Not yet recruiting | Phase 2 | 2025-01-20 | NCT06783257 | |
| A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction | Postoperative Gastrointestinal Dysfunction | Recruiting | Phase 2 | 2025-01-20 | NCT06782594 | |
| A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Enrolling by invitation | Phase 2 / Phase 3 | 2025-01-01 | NCT06755515 | |
| A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors | Advanced Solid Tumors (Phase 1) | Not yet recruiting | Phase 1 | 2024-12-30 | NCT06752447 | |
| Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy | colorectal adenoma | Not yet recruiting | Phase 2 | 2024-12-09 | NCT06722950 | |
| Phase I Study of LNF1901 in Advanced Malignant Tumors | Advanced Malignant Tumors | Not yet recruiting | Phase 1 | 2024-01-26 | NCT06226363 | |
| Phase I Study of XZ120 in Malignant Tumors | Advanced Malignancies | Not yet recruiting | Phase 1 | 2024-01-16 | NCT06206915 |